Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast phase 3 study in active Behçet's disease
2014-002108-25Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Behçet's disease (BD) comparing Apremilast with Placebo (2 arms). Primary endpoint: Area under the curve for the number of oral ulcers from baseline through Week 12. Started Nov 2014; status: completed.
02
Drugs
apremilast
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on 2014-002108-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002108-25.